CD274 and diffuse midline glioma: However, intratumoral heterogeneity (83, 84), low PD-L1 expression (85), low mutation burden (86), and chemotherapy-induced mutation properties (87, 88) in diffuse midline glioma might explain why no survival benefits have been observed with immune checkpoint inhibitors monotherapy (16, 89).